Google
Trusted Resources: News & Events
Latest announcements and gatherings
Investigational Therapy Altemia Achieves Main Endpoints in Pediatric Sickle Cell Trial
Sancilio Pharmaceuticals says its investigational therapy Altemia (SC411) achieved primary and secondary endpoints in a clinical trial with sickle cell patients 5 to 17 years old. Altemia is a combination of specific lipids designed to restore balance to the membrane of red blood cells that are damaged in sickle cell disease patients. The therapy uses Sancilio’s proprietary Advanced Lipid Technologies (ALT) platform.
The Phase 2 trial (NCT02973360) primary endpoint was the change from baseline in the concentration of fatty acids in the red blood cell membrane of patients treated with one of the three active doses of Altemia, or matching placebo. Fatty acids are a major component of cellular membrane.
+myBinderRelated Content
-
sicklecell101Pins from sicklecell101 on Pinterest...
-
How to Talk to Your Child About Hydroxyureahttps://www.youtube.com/watch?v=_apTt2j0...
-
Statement from FDA Commissioner on agency’s efforts to advance development of gene therapiesOnce just a theory, gene therapies are...
-
Dyspareunia is Associated With Chronic Pain in Premenopausal Women With Sickle Cell DiseaseObjectives: Pain is common in women wit...
-
The State-of-the-Art Methodology Behind New Sickle Cell Disease GuidelinesSickle cell disease (SCD) is an inherite...
-
Siklos (hydroxyurea) now available through ProCare Pharmacy Care’s Siklos At Home programMedunik USA announced today that...
-
New Guidelines for Managing Sickle Cell Disease Presented at ACP Internal Medicine MeetingNew guidelines for therapeutic strategie...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.